18F-DCFPyL与Na18F PET在前列腺癌骨转移检测中的前瞻性对比
该前瞻性研究对进展性转移性前列腺癌患者序贯行PSMA靶向18F-DCFPyL PET/CT与Na18F PET/CT,由两名读片者共识中心判读骨病灶。共16例入组、15例完成两种显像,识别405个可疑骨病灶;两种方法对骨病灶检测敏感性几乎相同,PSMA靶向PET可提供更多软组织病变信息。
要点
- 15例完成两种PET/CT,共识别405个可疑前列腺癌骨病灶。
- 18F-DCFPyL PET骨病灶明确阳性391个(96.5%),Na18F PET为388个(95.8%)。
- PSMA靶向PET额外提供软组织病变信息,已行PSMA PET后Na18F附加值可能有限。
核心结论
- 18F-DCFPyL PET/CT与Na18F PET/CT对转移性前列腺癌患者骨病灶检测敏感性几乎相同。
- PSMA靶向PET可提供更多软组织病变信息,已行PSMA靶向PET后再行Na18F显像可能附加值有限。
研究设计与样本
- 前瞻性研究,纳入进展性转移性前列腺癌患者,两种PET/CT扫描间隔在24小时内完成。
- 采用两名读片者共识中心判读,识别两种扫描上提示前列腺癌累及的所有骨病灶。
- 记录骨病灶最大SUV(按体重校正的SUVmax)和按瘦体重校正的SULmax,并记录软组织病变的SUVmax、SULmax及PSMA-RADS v1.0评分。
- 两种扫描数据比较采用广义估计方程。
- 共16例符合全部纳入标准入组,其中15例(93.8%)完成两种PET放射性示踪剂显像。
主要发现
- 至少一种扫描共识别405个提示前列腺癌累及的骨病灶。
- 18F-DCFPyL PET/CT上391个(96.5%)明确阳性、4个(1.0%)可疑阳性、10个(2.5%)阴性。
- Na18F PET/CT上388个(95.8%)明确阳性、4个(1.0%)可疑阳性、13个(3.2%)阴性。
- 18F-DCFPyL PET明确阴性病灶中8/10(80.0%)为硬化性、2/10(20.0%)为浸润性或骨髓性。
- Na18F PET明确阴性病灶中12/13(92.3%)为浸润性或骨髓性、1/13(7.7%)为溶骨性;另识别78个PSMA-RADS-4、17个PSMA-RADS-5和1个PSMA-RADS-3C软组织病灶。
关键数值与推荐
- 骨病灶判读分类包括明确阳性、可疑阳性和阴性,并记录SUVmax与SULmax。
- 软组织病灶记录SUVmax、SULmax及PSMA-RADS版本1.0评分,包括PSMA-RADS-3C、4、5。
临床怎么用
- 在转移性前列腺癌骨病灶检测中,18F-DCFPyL PET/CT与Na18F PET/CT敏感性几乎相同。
- PSMA靶向PET可同时评估软组织病变,已行PSMA靶向PET后追加Na18F显像的额外价值可能有限。
局限性
- 研究样本量较小,共16例入组、15例完成两种显像。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone metastases in prostate cancer (PCa) have important prognostic significance, and imaging modalities used for PCa staging should have high sensitivity for detecting such lesions. Prostate-specific membrane antigen (PSMA)-targeted PET radiotracers are promising new agents for imaging PCa. We undertook a head-to-head comparison of PSMA-targeted 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET to Na18F PET to determine which modality was more sensitive for the detection of lesions suggestive of bone metastases in a group of patients with metastatic PCa. Methods: Patients with progressive, metastatic PCa were prospectively imaged with both 18F-DCFPyL and Na18F PET/CT, with both scans occurring within 24 h of each other. A consensus 2-reader central review was performed to identify all bone lesions suggestive of sites of PCa involvement on both scans, and maximized SUVs corrected for body weight (SUVmax) and lean body mass (SULmax) were recorded. Soft-tissue lesions were also noted on both scans, and SUVmax, SULmax, and PSMA reporting and data system (RADS) version 1.0 scores were recorded. Data from the 2 scans were compared using a generalized estimating equation. Results: In total, 16 patients meeting all inclusion criteria were enrolled in this study, and 15 of the 16 (93.8%) were imaged with both PET radiotracers. In total, 405 bone lesions suggestive of sites of PCa were identified on at least 1 scan. On 18F-DCFPyL PET/CT, 391 (96.5%) were definitively positive, 4 (1.0%) were equivocally positive, and 10 (2.5%) were negative. On Na18F PET/CT, the corresponding values were 388 (95.8%), 4 (1.0%), and 13 (3.2%). Of the definitively negative lesions on 18F-DCFPyL PET, 8 of 10 (80.0%) were sclerotic and 2 of 10 (20.0%) were infiltrative or marrow-based. Additionally, 12 of 13 (92.3%) of the definitively negative lesions on Na18F PET were infiltrative or marrow-based and 1 of 13 (7.7%) was lytic. Also identified were 78 PSMA-RADS-4, 17 PSMA-RADS-5, and 1 PSMA-RADS-3C soft-tissue lesions. Conclusion: PET/CT imaging using 18F-DCFPyL and Na18F PET had nearly identical sensitivities for the detection of bone lesions in patients with metastatic PCa. As would be expected, PSMA-targeted PET provides more information on soft-tissue disease. There may be little additional value to imaging PCa patients with Na18F after a PSMA-targeted PET scan has already been performed.
引用
- Rowe SP, Li X, Trock BJ, et al. Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. J Nucl Med. 2019. PMID: 31451492. doi:10.2967/jnumed.119.227793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。